StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$26.71−1.02 (-3.70%)

Close on Nov 20, 2026Market cap $4.64BP/E –Yield –

Cogent Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cogent Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$309.24M. For fiscal 2025 it was -$266.00M. The highest annual figure on record is -$26.75M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$266.00M–
FY2024Dec 31, 2024-$208.36M–
FY2023Dec 31, 2023-$156.42M–
FY2022Dec 31, 2022-$125.50M–
FY2021Dec 31, 2021-$60.48M–
FY2019Dec 31, 2019-$41.55M–
FY2018Dec 31, 2018-$33.04M–
FY2017Dec 31, 2017-$26.75M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$77.64M–
Q1 FY2026Mar 31, 2026-$87.33M–
Q4 FY2025Dec 31, 2025-$79.92M–
Q3 FY2025Sep 30, 2025-$64.35M–
Q2 FY2025Jun 30, 2025-$54.67M–
Q1 FY2025Mar 31, 2025-$67.06M–
Q4 FY2024Dec 31, 2024-$60.65M–
Q3 FY2024Sep 30, 2024-$52.26M–
Q2 FY2024Jun 30, 2024-$42.85M–
Q1 FY2024Mar 31, 2024-$52.60M–
Q4 FY2023Dec 31, 2023-$44.39M–
Q3 FY2023Sep 30, 2023-$38.09M–
Q2 FY2023Jun 30, 2023-$33.32M–
Q1 FY2023Mar 31, 2023-$40.62M–
Q4 FY2022Dec 31, 2022-$31.38M–
Q3 FY2022Sep 30, 2022-$37.75M–
Q2 FY2022Jun 30, 2022-$27.60M–
Q1 FY2022Mar 31, 2022-$28.78M–
Q4 FY2021Dec 31, 2021-$21.21M–
Q3 FY2021Sep 30, 2021-$15.27M–
Q4 FY2019Dec 31, 2019-$8.46M–
Q3 FY2019Sep 30, 2019-$10.19M–
Q2 FY2019Jun 30, 2019-$11.34M–
Q1 FY2019Mar 31, 2019-$11.56M–
Q4 FY2018Dec 31, 2018-$9.02M–
Q3 FY2018Sep 30, 2018-$7.66M–
Q2 FY2018Jun 30, 2018-$8.30M–
Q1 FY2018Mar 31, 2018-$8.06M–
Q4 FY2017Dec 31, 2017-$6.62M–
Q3 FY2017Sep 30, 2017-$6.57M–
Q2 FY2017Jun 30, 2017-$5.98M–
Q1 FY2017Mar 31, 2017-$7.59M–

More Cogent Biosciences figures

See a number that looks wrong?